[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"male-sexual-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:male-sexual-dysfunction":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100638532","pelvic-floor-therapies-for-lifelong-premature-ejaculation-100638532",false,"NCT07627438","Pelvic Floor Therapies for Lifelong Premature Ejaculation","Electromagnetic Pelvic Floor Stimulation Versus Biofeedback-Assisted and Conventional Pelvic Floor Muscle Training in Men With Lifelong Premature Ejaculation: A Randomized Controlled Trial","PE-PFMT","Inclusion Criteria:\n\n* Men aged 18 to 50 years.\n* Diagnosis of lifelong premature ejaculation.\n* Intravaginal ejaculatory latency time less than 1 minute.\n* Ability and willingness to comply with the treatment protocol and follow-up visits.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Erectile dysfunction.\n* Neurological disease.\n* Previous pelvic surgery.","MALE","18 Years","50 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled trial will compare three pelvic floor-based treatment modalities in men with lifelong premature ejaculation: electromagnetic pelvic floor stimulation, biofeedback-assisted pelvic floor muscle training, and conventional pelvic floor muscle training. A total of 150 men aged 18 to 50 years with lifelong premature ejaculation and stopwatch-measured intravaginal ejaculatory latency time of less than 1 minute will be randomly assigned to one of the three treatment groups. The primary outcome will be the change in intravaginal ejaculatory latency time from baseline to the end of treatment at 6 weeks. Secondary outcomes will include changes in Premature Ejaculation Diagnostic Tool score, International Index of Erectile Function-5 score, patient-reported ejaculatory control, sexual satisfaction, partner satisfaction, treatment adherence, and adverse events.",[28,29,30],"Premature Ejaculation","Lifelong Premature Ejaculation","Male Sexual Dysfunction",[32,33,34],"Pelvic floor muscle training","Biofeedback","Electromagnetic pelvic floor stimulation","RECRUITING","2026-05-30",{"date":38,"type":39},"2026-06-04","ACTUAL",{"date":41,"type":39},"2026-04-26",{"date":43,"type":22},"2027-04",{"name":45,"class":46},"Tanta University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100467736","emsella-chair-vs-sham-for-male-sexual-dysfunction-100467736","NCT05370651","Emsella Chair vs Sham for Male Sexual Dysfunction","A Single-Blind, Randomized Study of the BTL Emsella Chair Versus Sham for the Treatment of Male Sexual Dysfunction","Emsella_EJD","Inclusion Criteria:\n\n1. Able to read, understand, and provide written, dated, informed consent prior to screening, and be likely to comply with study protocol, including independently complete study questionnaires and communicate with study personnel about adverse events and other clinically important information.\n2. Men ≥ 18 years of age.\n3. Sexually active within the past 12 weeks and plan to be sexually active during the next 12 weeks.\n\n5\\. Self-reported ejaculatory dysfunction symptoms present \\>3 months 6. Self-reported failed conservative care of behavioral modifications and\u002For oral medications.\n\n7\\. Subject agrees not to start any new treatment for erectile dysfunction or ejaculatory dysfunction during the treatment and follow-up periods.\n\nExclusion Criteria:\n\n1. Botox® use in bladder or pelvic floor muscles in the past year\n2. Subject weighs greater than 330 pounds, due to weight limits of the Emsella Chair.\n3. Pulmonary insufficiency, defined as difficulty breathing and fatigue, especially during exercise; chest pain, such as squeezing, pressure of tightness; the sensation of rapid or irregular heartbeat (palpitations); swelling of the legs or feet; dizziness or fainting; and\u002For bluish discoloration of the nails and\u002For lips (cyanosis)\n4. Any condition that causes a lack of normal skin sensation to the pelvis, thigh, or buttocks.\n5. Major metal implants such as: metal plates, screws, joint replacements, implanted cardiac pacemakers, drug pumps, neurostimulators, electronic implants, defibrillators, and metal implants in the pelvic area. Patients with other metal implants will be evaluated by the investigator for inclusion in the study.\n6. Previous or current penile prosthesis.\n7. Subject has a piercing between the waist and knees and is not willing to remove it before each treatment\n8. Active urethral diverticula\n9. Known history of urethral stricture disease\n10. Currently healing from surgical procedures where muscle contraction may disrupt the healing process\n11. Subject is currently receiving treatment for a malignant tumor that would interfere with study participation.\n12. Subject has used the BTL EMSELLA device previously\n13. Subject has sexual dysfunction of neurogenic etiology, such as multiple sclerosis, spina bifida, Parkinson's, spinal cord injury, diabetic neuropathy, neurogenic bladder etc.\n14. Current use of neuromodulation therapy, including Interstim and percutaneous tibial nerve stimulation (PTNS), for bladder symptoms within 3 months of screening visit (if past sacral\u002Fpudendal implant, must be explanted)\n15. Currently participating in an investigational study that may impact study results or previously received an investigational drug or treatment within 30 days of the Screening Visit\n16. Current or history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation\n\n    * Note for the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.",{"count":57,"type":22},117,[25],"We will be performing this study in 2 phases: Phase 1 will be an open label pilot study of 10 male participants. All participants in the pilot study will receive active treatment. If data from the pilot study is suggestive of symptom improvement, we will continue on to phase 2, which is a sham controlled, randomized blinded study. Participants in phase 2 will be randomized to receive either active treatment or sham. Potentially a total of 117 participants for both phases will be enrolled.\n\nThe purpose of this study is to compare the Emsella Chair to sham and to determine whether electromagnetic technology is effective in the treatment of sexual dysfunction, specifically erectile dysfunction (EjD) in men.",[30,61],"Ejaculatory Dysfunction",[30],"2025-12-05",{"date":65,"type":39},"2025-12-11",{"date":67,"type":39},"2022-12-14",{"date":69,"type":22},"2027-12",{"name":71,"class":46},"Corewell Health East"]